5 Stocks Pulling The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 58 points (-0.4%) at 15,461 as of Wednesday, Aug. 7, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 785 issues advancing vs. 2,161 declining with 94 unchanged.

The Drugs industry currently sits down 0.6% versus the S&P 500, which is down 0.4%. A company within the industry that fell today was Biogen Idec ( BIIB), up 0.8%. Top gainers within the industry include Santarus ( SNTS), up 8.5%, Biomarin Pharmaceutical ( BMRN), up 2.1%, Celgene Corporation ( CELG), up 1.4%, Amgen ( AMGN), up 1.8% and Sanofi ( SNY), up 0.8%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Inovio Pharmaceuticals ( INO) is one of the companies pushing the Drugs industry lower today. As of noon trading, Inovio Pharmaceuticals is down $0.66 (-25.4%) to $1.94 on heavy volume. Thus far, 22.0 million shares of Inovio Pharmaceuticals exchanged hands as compared to its average daily volume of 5.2 million shares. The stock has ranged in price between $1.77-$2.29 after having opened the day at $2.29 as compared to the previous trading day's close of $2.60.

Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. Inovio Pharmaceuticals has a market cap of $539.8 million and is part of the health care sector. Shares are up 500.6% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Inovio Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Inovio Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and feeble growth in its earnings per share. Get the full Inovio Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, AstraZeneca ( AZN) is down $0.41 (-0.8%) to $50.11 on average volume. Thus far, 1.0 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $50.04-$50.49 after having opened the day at $50.22 as compared to the previous trading day's close of $50.52.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $63.4 billion and is part of the health care sector. Shares are up 6.9% year to date as of the close of trading on Tuesday. Currently there is 1 analyst that rates AstraZeneca a buy, 2 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Illumina ( ILMN) is down $1.01 (-1.3%) to $78.01 on light volume. Thus far, 263,622 shares of Illumina exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $77.62-$79.18 after having opened the day at $79.18 as compared to the previous trading day's close of $79.02.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $9.8 billion and is part of the health care sector. Shares are up 41.0% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Illumina Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Onyx Pharmaceuticals ( ONXX) is down $3.27 (-2.5%) to $128.75 on heavy volume. Thus far, 2.5 million shares of Onyx Pharmaceuticals exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $128.30-$132.98 after having opened the day at $131.86 as compared to the previous trading day's close of $132.02.

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. Onyx Pharmaceuticals has a market cap of $9.7 billion and is part of the health care sector. Shares are up 74.8% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Onyx Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Onyx Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. Get the full Onyx Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Bristol-Myers Squibb Company ( BMY) is down $0.36 (-0.8%) to $43.78 on light volume. Thus far, 2.1 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10.7 million shares. The stock has ranged in price between $43.69-$44.07 after having opened the day at $43.96 as compared to the previous trading day's close of $44.14.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $71.8 billion and is part of the health care sector. Shares are up 35.4% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%